Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Operating Margin (2020 - 2025)

Historic Operating Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 48.67%.

  • Apellis Pharmaceuticals' Operating Margin rose 726900.0% to 48.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.91%, marking a year-over-year increase of 391400.0%. This contributed to the annual value of 21.11% for FY2024, which is 1092800.0% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Operating Margin of 48.67% as of Q3 2025, which was up 726900.0% from 18.65% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Operating Margin ranged from a high of 48.67% in Q3 2025 and a low of 31185.71% during Q2 2021
  • In the last 5 years, Apellis Pharmaceuticals' Operating Margin had a median value of 125.49% in 2023 and averaged 2090.58%.
  • Data for Apellis Pharmaceuticals' Operating Margin shows a peak YoY increase of 302751400bps (in 2022) and a maximum YoY decrease of -5755900bps (in 2022) over the last 5 years.
  • Apellis Pharmaceuticals' Operating Margin (Quarter) stood at 148.29% in 2021, then tumbled by -388bps to 723.88% in 2022, then skyrocketed by 92bps to 57.74% in 2023, then soared by 79bps to 12.31% in 2024, then surged by 495bps to 48.67% in 2025.
  • Its Operating Margin stands at 48.67% for Q3 2025, versus 18.65% for Q2 2025 and 49.96% for Q1 2025.